Comparative Pharmacology
Head-to-head clinical analysis: CLARITIN versus CLARITIN REDITABS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLARITIN versus CLARITIN REDITABS.
CLARITIN vs CLARITIN REDITABS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Loratadine is a long-acting tricyclic antihistamine with selective peripheral H1 receptor antagonistic activity. It inhibits histamine release from mast cells and reduces allergic responses.
Loratadine is a selective antagonist of peripheral histamine H1 receptors, reducing allergic response symptoms by inhibiting histamine release from mast cells.
10 mg orally once daily for adults and children ≥6 years.
10 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life 27 hours (range 22-30 hours); clinical context: allows once-daily dosing, steady state reached in 5-7 days
Terminal elimination half-life: 8–28 hours (mean ~14 hours for loratadine; active metabolite desloratadine: 14–26 hours). Context: Allows once-daily dosing; half-life extended in hepatic impairment.
Renal 40% as metabolites, fecal 40% as metabolites, biliary <5% as unchanged drug
Renal (approximately 40% as metabolites) and fecal (approximately 40% as metabolites). Parent drug and active metabolite (desloratadine) are excreted in urine (27% total) and feces (40% total).
Category C
Category C
Antihistamine
Antihistamine